• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

18-64 岁高危成年人疫苗接种率提高的成本效益:基于模型的决策分析。

Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.

机构信息

Department of Medicine, University of Pittsburgh School of Medicine, 200 Meyran Ave., Suite 200, Pittsburgh, PA, 15213, USA.

Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

出版信息

BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.

DOI:10.1186/s12879-018-2967-2
PMID:29370768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5785845/
Abstract

BACKGROUND

Adults aged 18-64 years with comorbid conditions are at high risk for complications of certain vaccine-preventable diseases, including influenza and pneumococcal disease. The 4 Pillars™ Practice Transformation Program (4 Pillars Program) increases uptake of pneumococcal polysaccharide vaccine, influenza vaccine and tetanus-diphtheria-acellular pertussis vaccine by 5-10% among adults with high-risk medical conditions, but its cost-effectiveness is unknown.

METHODS

A decision tree model estimated the cost-effectiveness of implementing the 4 Pillars Program in primary care practices compared to no program for a population of adults 18-64 years of age at high risk of illness complications over a 10 year time horizon. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial in diverse practices in 2 U.S. cities. One-way and probabilistic sensitivity analyses were conducted.

RESULTS

From a third-party payer perspective, which considers direct medical costs, the 4 Pillars Program cost $28,301 per quality-adjusted life year gained; from a societal perspective, which adds direct nonmedical and indirect costs, the program was cost saving and more effective than no intervention. Cost effectiveness results favoring the program were robust in sensitivity analyses. From a public health standpoint, the model predicted that the intervention reduced influenza cases by 1.4%, with smaller decreases in pertussis and pneumococcal disease cases.

CONCLUSION

The 4 Pillars Practice Transformation Program is an economically reasonable, and perhaps cost saving, strategy for protecting the health of adults aged < 65 years with high-risk medical conditions.

摘要

背景

18-64 岁患有合并症的成年人患某些可通过疫苗预防的疾病(包括流感和肺炎球菌病)并发症的风险较高。四支柱实践转型计划(4 Pillars Program)可将患有高危医疗条件的成年人对肺炎球菌多糖疫苗、流感疫苗和破伤风、白喉、无细胞百日咳疫苗的接种率提高 5-10%,但其成本效益尚不清楚。

方法

决策树模型估计了在初级保健实践中实施 4 Pillars Program 与不实施该计划相比,在 10 年时间内对有患病并发症高风险的 18-64 岁成年人人群的成本效益。疫苗接种率和干预成本来自于在美国两个城市的多样化实践中的一项随机对照群集试验。进行了单因素和概率敏感性分析。

结果

从第三方支付者的角度来看,考虑直接医疗成本,4 Pillars Program 每获得一个质量调整生命年的成本为 28,301 美元;从社会角度来看,加上直接非医疗和间接成本,该计划具有成本效益,并且比不干预更有效。在敏感性分析中,有利于该计划的成本效益结果是稳健的。从公共卫生的角度来看,该模型预测该干预措施将使流感病例减少 1.4%,而百日咳和肺炎球菌病病例的减少幅度较小。

结论

四支柱实践转型计划是一种经济合理且可能具有成本效益的策略,可以保护 18-64 岁有高危医疗条件的成年人的健康。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1226/5785845/2eb9ab4357f2/12879_2018_2967_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1226/5785845/612d8426b1c9/12879_2018_2967_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1226/5785845/2eb9ab4357f2/12879_2018_2967_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1226/5785845/612d8426b1c9/12879_2018_2967_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1226/5785845/2eb9ab4357f2/12879_2018_2967_Fig2_HTML.jpg

相似文献

1
Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.18-64 岁高危成年人疫苗接种率提高的成本效益:基于模型的决策分析。
BMC Infect Dis. 2018 Jan 25;18(1):52. doi: 10.1186/s12879-018-2967-2.
2
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.“四支柱实践转型计划”提高65岁及以上成年人疫苗接种率的成本效益分析
J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.
3
Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.基于实践的干预措施提高 65 岁以下成年人疫苗接种率的成本效益。
Hum Vaccin Immunother. 2017 Oct 3;13(10):2207-2212. doi: 10.1080/21645515.2017.1356526.
4
Using the 4 Pillars™ Practice Transformation Program to increase adolescent human papillomavirus, meningococcal, tetanus-diphtheria-pertussis and influenza vaccination.使用“四大支柱”™实践转型计划来提高青少年人乳头瘤病毒、脑膜炎球菌、破伤风-白喉-百日咳和流感疫苗接种率。
Vaccine. 2017 Oct 27;35(45):6180-6186. doi: 10.1016/j.vaccine.2017.09.039. Epub 2017 Sep 22.
5
Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013.2013年美国四种主要成人疫苗可预防疾病的估计人力和经济负担
J Prim Prev. 2015 Aug;36(4):259-73. doi: 10.1007/s10935-015-0394-3.
6
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.免疫功能低下成人患者中,接种 13 价肺炎球菌结合疫苗替代 23 价肺炎球菌多糖疫苗的成本效益分析。
Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.
7
Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.50 岁人群中接种双联流感和肺炎球菌疫苗的成本效益分析。
Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.
8
Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.克罗地亚肺炎球菌结合疫苗接种的成本效益
Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.
9
The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.在中国年度流感流行和流感大流行期间接种7价肺炎球菌疫苗(PCV7)对健康和经济的影响。
BMC Infect Dis. 2015 Jul 24;15:284. doi: 10.1186/s12879-015-1021-x.
10
Cost-effectiveness analysis of universal maternal immunization with tetanus-diphtheria-acellular pertussis (Tdap) vaccine in Brazil.巴西使用破伤风-白喉-无细胞百日咳(Tdap)疫苗进行普遍孕产妇免疫的成本效益分析。
Vaccine. 2016 Mar 18;34(13):1531-1539. doi: 10.1016/j.vaccine.2016.02.026. Epub 2016 Feb 17.

引用本文的文献

1
Lifetime Health and Economic Burden of Invasive Pneumococcal Diseases Attributable to V116 Serotypes Among Adults in the United States.美国成年人中V116血清型侵袭性肺炎球菌疾病的终生健康和经济负担
Infect Dis Ther. 2024 Jul;13(7):1501-1514. doi: 10.1007/s40121-024-00988-1. Epub 2024 May 25.
2
Public health impact and return on investment of Belgium's pediatric immunization program.比利时儿科免疫计划的公共卫生影响和投资回报。
Front Public Health. 2023 Jun 22;11:1032385. doi: 10.3389/fpubh.2023.1032385. eCollection 2023.
3
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines.

本文引用的文献

1
Using a Mixed Methods Approach to Examine Practice Characteristics Associated With Implementation of an Adult Immunization Intervention Using the 4 Pillars Practice Transformation Program.采用混合方法研究与使用“四大支柱实践转型计划”实施成人免疫接种干预措施相关的实践特征。
J Healthc Qual. 2017 May/Jun;39(3):153-167. doi: 10.1097/JHQ.0000000000000071.
2
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older.“四支柱实践转型计划”提高65岁及以上成年人疫苗接种率的成本效益分析
J Am Geriatr Soc. 2017 Apr;65(4):763-768. doi: 10.1111/jgs.14588. Epub 2016 Dec 26.
3
加拿大胃肠病学协会炎症性肠病(IBD)患者免疫接种临床实践指南 - 第2部分:灭活疫苗
J Can Assoc Gastroenterol. 2021 Jul 29;4(4):e72-e91. doi: 10.1093/jcag/gwab016. eCollection 2021 Aug.
4
Reducing the infectious diseases burden through "life course approach vaccination" in India-a perspective.从一个视角看,通过“生命历程方法接种疫苗”减轻印度的传染病负担
AIMS Public Health. 2021 Aug 3;8(3):553-562. doi: 10.3934/publichealth.2021045. eCollection 2021.
5
Pertussis in Individuals with Co-morbidities: A Systematic Review.合并症患者的百日咳:一项系统综述
Infect Dis Ther. 2021 Sep;10(3):1141-1170. doi: 10.1007/s40121-021-00465-z. Epub 2021 Jun 12.
6
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysis.进一步研究成人肺炎球菌疫苗接种率改善项目是否值得?价值信息分析。
Vaccine. 2021 Jun 16;39(27):3608-3613. doi: 10.1016/j.vaccine.2021.05.037. Epub 2021 May 25.
7
Cost-effectiveness of Interventions to Increase HPV Vaccine Uptake.提高 HPV 疫苗接种率的干预措施的成本效益。
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-0395. Epub 2020 Nov 16.
8
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 Years.未满足需求人群和普通人群中 < 65 岁老年人的肺炎球菌疫苗接种和接种率改善计划的成本效益分析。
J Community Health. 2020 Feb;45(1):111-120. doi: 10.1007/s10900-019-00716-8.
9
Decreasing influenza vaccine coverage among adults with high-risk chronic diseases in Spain from 2014 to 2017.西班牙 2014 至 2017 年高风险慢性病成人的流感疫苗接种率下降
Hum Vaccin Immunother. 2020;16(1):95-99. doi: 10.1080/21645515.2019.1646577. Epub 2019 Oct 22.
Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars™ practice Transformation Program.
在一项使用“四大支柱”™实践转型计划的随机对照整群试验中改善青少年人乳头瘤病毒疫苗接种情况。
Vaccine. 2017 Jan 3;35(1):109-117. doi: 10.1016/j.vaccine.2016.11.018. Epub 2016 Nov 18.
4
Using the 4 pillars™ practice transformation program to increase adult influenza vaccination and reduce missed opportunities in a randomized cluster trial.在一项随机整群试验中,使用“4支柱™”实践转化项目来提高成人流感疫苗接种率并减少错失的机会。
BMC Infect Dis. 2016 Nov 3;16(1):623. doi: 10.1186/s12879-016-1940-1.
5
Using the 4 Pillars Practice Transformation Program to Increase Pneumococcal Immunizations for Older Adults: A Cluster-Randomized Trial.使用四支柱实践转型计划提高老年人肺炎球菌疫苗接种率:一项整群随机试验。
J Am Geriatr Soc. 2017 Jan;65(1):114-122. doi: 10.1111/jgs.14451. Epub 2016 Oct 18.
6
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.《健康与医疗领域成本效益分析的实施、方法学实践和报告推荐:第二版》。
JAMA. 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195.
7
Using the 4 Pillars™ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial.在一项随机对照整群试验中,使用“4支柱™实践转型计划”来提高成人破伤风、白喉和无细胞百日咳疫苗(Tdap)的接种率。
Vaccine. 2016 Sep 22;34(41):5026-5033. doi: 10.1016/j.vaccine.2016.07.053. Epub 2016 Aug 26.
8
Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.13价肺炎球菌结合疫苗在美国50岁及以上成年人中的增量成本效益
J Gen Intern Med. 2016 Aug;31(8):901-8. doi: 10.1007/s11606-016-3651-0. Epub 2016 Mar 14.
9
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.成人人群疫苗接种覆盖率监测 - 美国,2014 年。
MMWR Surveill Summ. 2016 Feb 5;65(1):1-36. doi: 10.15585/mmwr.ss6501a1.
10
Maintenance of Increased Childhood Influenza Vaccination Rates 1 Year After an Intervention in Primary Care Practices.初级保健机构干预1年后儿童流感疫苗接种率持续上升的维持情况
Acad Pediatr. 2016 Jan-Feb;16(1):57-63. doi: 10.1016/j.acap.2015.03.010.